89bio, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 101 rows in 2025. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2025-10-30: Reporting owner Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2025-10-30: Reporting owner Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2025-10-30: Reporting owner Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2025-10-30: Reporting owner Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-10-30 | Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $21.40 exercise price | 2025-11-03 | |
| 2025-10-30 | Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $24.29 exercise price | 2025-11-03 | |
| 2025-10-30 | Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $24.16 exercise price | 2025-11-03 | |
| 2025-10-30 | Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −25,000 0 owned after | $2.64 exercise price | 2025-11-03 | |
| 2025-10-30 | Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,400 0 owned after | $14.70 exercise price | 2025-11-03 | |
| 2025-10-30 | Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,150 0 owned after | $9.98 exercise price | 2025-11-03 | |
| 2025-10-30 | Shah Rajeev M. | RA CAPITAL MANAGEMENT, L.P. | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-11-03 | |
| 2025-10-30 | LAPORTE KATHLEEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −25,000 0 owned after | $18.68 exercise price | 2025-10-30 | |
| 2025-10-30 | LAPORTE KATHLEEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $2.64 exercise price | 2025-10-30 | |
| 2025-10-30 | LAPORTE KATHLEEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,400 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | LAPORTE KATHLEEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,150 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | LAPORTE KATHLEEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,647 0 owned after | $1.93 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −2,933 0 owned after | $1.93 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −22,730 0 owned after | $3.11 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $21.40 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $24.29 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $24.16 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −25,000 0 owned after | $2.64 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,400 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,150 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −47,500 0 owned after | $32.50 exercise price | 2025-10-30 | |
| 2025-10-30 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −57,500 0 owned after | $23.01 exercise price | 2025-10-30 | |
| 2025-10-30 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −48,102 0 owned after | $4.44 exercise price | 2025-10-30 | |
| 2025-10-30 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −110,000 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −175,000 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −300,000 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Altschuler Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −40,000 0 owned after | $23.22 exercise price | 2025-10-30 | |
| 2025-10-30 | Altschuler Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $24.29 exercise price | 2025-10-30 | |
| 2025-10-30 | Altschuler Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $24.16 exercise price | 2025-10-30 | |
| 2025-10-30 | Altschuler Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −25,000 0 owned after | $2.64 exercise price | 2025-10-30 | |
| 2025-10-30 | Altschuler Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,400 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | Altschuler Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,150 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | Altschuler Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −120,231 0 owned after | $1.93 exercise price | 2025-10-30 | |
| 2025-10-30 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −132,242 0 owned after | $3.11 exercise price | 2025-10-30 | |
| 2025-10-30 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −170,000 0 owned after | $32.50 exercise price | 2025-10-30 | |
| 2025-10-30 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −203,750 0 owned after | $23.01 exercise price | 2025-10-30 | |
| 2025-10-30 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −220,000 0 owned after | $4.44 exercise price | 2025-10-30 | |
| 2025-10-30 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −300,000 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −605,000 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −848,000 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | McWherter Charles Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −67,700 0 owned after | $8.39 exercise price | 2025-10-30 | |
| 2025-10-30 | McWherter Charles Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Atkinson Edward Morrow III Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −20,000 0 owned after | $4.44 exercise price | 2025-10-30 | |
| 2025-10-30 | Atkinson Edward Morrow III Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,400 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | Atkinson Edward Morrow III Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,150 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | Atkinson Edward Morrow III Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Zoth Lota S. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −20,000 0 owned after | $24.05 exercise price | 2025-10-30 | |
| 2025-10-30 | Zoth Lota S. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $24.16 exercise price | 2025-10-30 | |
| 2025-10-30 | Zoth Lota S. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −25,000 0 owned after | $2.64 exercise price | 2025-10-30 | |
| 2025-10-30 | Zoth Lota S. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,400 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | Zoth Lota S. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,150 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | Zoth Lota S. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −4,063 0 owned after | $3.11 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −3,312 0 owned after | $3.11 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $32.50 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −67,500 0 owned after | $23.01 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −70,000 0 owned after | $4.44 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −120,000 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −195,000 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −320,000 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −26,400 0 owned after | $10.58 exercise price | 2025-10-30 | |
| 2025-10-30 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −17,500 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Babler Martin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −67,700 0 owned after | $8.86 exercise price | 2025-10-30 | |
| 2025-10-30 | Babler Martin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | DiRocco Derek Director | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $21.40 exercise price | 2025-10-30 | |
| 2025-10-30 | DiRocco Derek Director | 4 | Stock Option (Right to Buy) Derivative · Indirect · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,000 0 owned after | $24.29 exercise price | 2025-10-30 | |
| 2025-10-30 | DiRocco Derek Director | 4 | Stock Option (Right to Buy) Derivative · Indirect · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,500 0 owned after | $24.16 exercise price | 2025-10-30 | |
| 2025-10-30 | DiRocco Derek Director | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −25,000 0 owned after | $2.64 exercise price | 2025-10-30 | |
| 2025-10-30 | DiRocco Derek Director | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −27,400 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | DiRocco Derek Director | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,150 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | DiRocco Derek Director | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −56,400 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Sarena Francis Willard Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −350,000 0 owned after | $8.39 exercise price | 2025-10-30 | |
| 2025-10-30 | Sarena Francis Willard Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −215,000 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-30 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −98,204 0 owned after | $1.93 exercise price | 2025-10-30 | |
| 2025-10-30 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −39,037 0 owned after | $3.11 exercise price | 2025-10-30 | |
| 2025-10-30 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,000 0 owned after | $32.50 exercise price | 2025-10-30 | |
| 2025-10-30 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −67,500 0 owned after | $23.01 exercise price | 2025-10-30 | |
| 2025-10-30 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −70,000 0 owned after | $4.44 exercise price | 2025-10-30 | |
| 2025-10-30 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −120,000 0 owned after | $14.70 exercise price | 2025-10-30 | |
| 2025-10-30 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −195,000 0 owned after | $9.98 exercise price | 2025-10-30 | |
| 2025-10-30 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −320,000 0 owned after | $9.60 exercise price | 2025-10-30 | |
| 2025-10-22 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −76,901 0 owned after | $3.11 exercise price | 2025-10-23 | |
| 2025-10-22 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,898 48,102 owned after | $4.44 exercise price | 2025-10-23 | |
| 2025-02-03 | RA Capital Healthcare Fund LP | RA Capital Nexus Fund, L.P. | Kolchinsky Peter | RA CAPITAL MANAGEMENT, L.P. | Shah Rajeev M. Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-03 | DiRocco Derek Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-03 | Zoth Lota S. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-03 | Babler Martin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-03 | Altschuler Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-03 | LAPORTE KATHLEEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-03 | Hayden Michael R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-03 | Atkinson Edward Morrow III Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-03 | McWherter Charles Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,400 56,400 owned after | $9.60 exercise price | 2025-02-05 | |
| 2025-02-01 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · By Spouse | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,500 17,500 owned after | $9.60 exercise price | 2025-02-19 | |
| 2025-02-01 | Martins Ryan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +300,000 300,000 owned after | $9.60 exercise price | 2025-02-04 | |
| 2025-02-01 | Le-Nguyen Quoc Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +320,000 320,000 owned after | $9.60 exercise price | 2025-02-04 | |
| 2025-02-01 | PALEKAR ROHAN Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +848,000 848,000 owned after | $9.60 exercise price | 2025-02-04 | |
| 2025-02-01 | Mansbach Harry H Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +320,000 320,000 owned after | $9.60 exercise price | 2025-02-04 |